Compare Genovis AB with Similar Stocks
Dashboard
1
Flat results in Dec 25
- INTEREST(9M) At SEK 0.9 MM has Grown at inf%
- OPERATING CASH FLOW(Y) Lowest at SEK 32.03 MM
- EPS(Q) Lowest at SEK 0
2
With ROE of 11.29%, it has a very expensive valuation with a 5.88 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,105 Million (Small Cap)
52.00
NA
0.00%
-0.58
8.65%
4.07
Revenue and Profits:
Net Sales:
40 Million
(Quarterly Results - Dec 2025)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.09%
0%
-15.09%
6 Months
-20.53%
0%
-20.53%
1 Year
-7.69%
0%
-7.69%
2 Years
-44.62%
0%
-44.62%
3 Years
-71.01%
0%
-71.01%
4 Years
-64.98%
0%
-64.98%
5 Years
-50.0%
0%
-50.0%
Genovis AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.14%
EBIT Growth (5y)
40.90%
EBIT to Interest (avg)
26.63
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
0.59
Tax Ratio
35.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
46.73%
ROE (avg)
18.20%
Valuation key factors
Factor
Value
P/E Ratio
52
Industry P/E
Price to Book Value
5.88
EV to EBIT
48.58
EV to EBITDA
34.84
EV to Capital Employed
17.01
EV to Sales
10.15
PEG Ratio
0.93
Dividend Yield
NA
ROCE (Latest)
35.02%
ROE (Latest)
11.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
40.30
27.50
46.55%
Operating Profit (PBDIT) excl Other Income
12.70
8.30
53.01%
Interest
0.40
0.40
Exceptional Items
0.00
0.00
Consolidate Net Profit
6.90
8.00
-13.75%
Operating Profit Margin (Excl OI)
224.10%
172.50%
5.16%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 46.55% vs -4.84% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -13.75% vs 56.86% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
128.90
130.40
-1.15%
Operating Profit (PBDIT) excl Other Income
39.80
39.30
1.27%
Interest
1.00
4.00
-75.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
23.50
32.90
-28.57%
Operating Profit Margin (Excl OI)
213.20%
221.20%
-0.80%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -1.15% vs -17.57% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -28.57% vs -46.50% in Dec 2024
About Genovis AB 
Genovis AB
Pharmaceuticals & Biotechnology
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Company Coordinates 
Company Details
Medicon Village, Scheelevagen 2 , LUND None : 223 63
Registrar Details






